PMPlamen Mihaylov

Plamen Mihaylov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Plamen Mihaylov has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial intelligence in the estimation of fat content in liver biopsies for liver transplantation: a systematic review

    by Danielle M. Wilmes, Evan J. Catron, Robert P. Passarelli, Plamen Mihaylov, Ping Li, Wenjun Zhang, Yucel Yankol, Richard S. Mangus, Marc L. Melcher, Burcin Ekser

    Quantification of hepatic steatosis is an important measure for assessing the viability of donor livers for transplantation. Currently, this measurement is obtained by a pathologist’s visual inspection of a liver biopsy sample to estimate the level of disease progression. However, recent advancements in automated methods, particularly artificial intelligence (AI) programs, offer alternative approaches. This systematic review summarizes the available literature on the various AI programs that have been designed to quantify hepatic steatosis. The literature search was performed using PubMed, Embase, and MEDLINE, covering studies published from 2019 to 2024. The 14 included studies used AI to calculate hepatic steatosis from digitized biopsies, except one, which used gross intraoperative smartphone images of the entire liver and provided a measure of accuracy. The programs use either a form of machine learning or image analysis software to label and quantify areas of steatosis on images of liver biopsies, reporting measures such as percent macrosteatosis (%MaS), percent total steatosis, fat fraction, nonalcoholic fatty liver disease activity score, and steatosis proportionate area. Agreement between AI-generated and pathologist %MaS scores varied widely across studies, but pathologist scores tended to be considerably higher than AI scores. Multiple studies noted significant interobserver variability between pathologists. Two papers reported associations between AI steatosis scores and post-transplantation outcome measures. Current literature shows promise for the application of AI in quantifying hepatic steatosis. This development provides the prospect of a faster, more precise method of determining the level of steatosis, which would further optimize the use of livers for transplantation.

  • Renal Function in Sequential Living Kidney‐Then‐Liver Donors Undergoing Right Lobe Donation: A Two‐Center Case Study

    by Daisuke Imai, Zachary P. Rokop, Masaya Yokoyama, Amit Sharma, Plamen Mihaylov, John Powelson, Seung Duk Lee, Muhammad I. Saeed, Dhiren Kumar, Asif Sharfuddin, et al.

    Background: There are concerns regarding the potential impact of living donor hepatectomy on the kidney function of prior kidney donors. The current literature lacks comprehensive data on living liver following living kidney donation. Furthermore, the focus on left lobe donation in the literature does not fully represent the prevalent use of the right lobe graft for living liver transplants in the United States.Methods: We performed a retrospective chart review on all living liver donors who had previously donated a kidney at two US centers.Results: There were 14 sequential living kidney‐then‐liver donors. The median donor age was 49 years (range 35–59). Most of these (12 donors) were nondirected donations. The median follow‐up period was 24 months (range 1–129). The median interval between the donations was 32 months (range 17–154 months). All donors donated the right lobe with 43.5% (range 31.4%–49.9 %) of remnant liver volume. The overall donor complication rate was 43%, seen in six donors, with one Clavien–Dindo Grade IIIa complication (suture granuloma removal under local anesthesia). Two donors (14%) experienced stage 1 AKI, both resolving with supportive care. A decrease in eGFR greater than 10 mL/min/1.73 m2 over the follow‐up was observed in only one donor, who gained weight and was lost to follow‐up. Compensatory kidney hypertrophy was observed, with kidney volumetry showing an increase of 1.27 (1.09–1.39) times pre‐ versus post‐kidney donation and 1.08 times pre‐ versus post‐liver donation (1.01–1.16).Conclusions: Right lobe living liver donation in previous kidney donors might be safely performed in terms of midterm kidney function. Longer‐term assessment in a larger cohort would be necessary to have better insight into this unique donor group.


  • Letter to the Editor: Mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation—Are there other challenges?

    by Burcin Ekser, Serkan Sucu, Plamen Mihaylov, Juliet A. Emamaullee

    An abstract is unavailable. This article is available as a PDF only.

  • Open Access

    Impact of gut microbiota on liver transplantation

    by Serkan Sucu, Kerem E. Basarir, Plamen Mihaylov, Emre Balik, Jason T.C. Lee, Jonathan A. Fridell, Juliet A. Emamaullee, Burcin Ekser


  • Open Access

    Adenovirus-Related Fulminant Liver Failure After Kidney Transplantation

    by Plamen Mihaylov, Andrew J. Lutz, Federico Oppliger, Jingmei Lin

    Unusual clinical course Human adenovirus is a well-known pathogen that can potentially lead to severe infection in immunocompromised patients. Adenovirus infections in solid-organ transplant recipients can range from asymptomatic to severe, prolonged, disseminated disease, and have a significant impact on morbidity, mortality, and graft survival. The clinical manifestations vary from asymptomatic and flu-like illness to severe life-threatening viremia with multi-organ failure. Post-transplant adenovirus infection is well described in kidney recipients, but in adult liver transplant recipients the impact of the virus is not well described. In this report, a case of disseminated adenovirus infection with subsequent fatal acute liver failure in a post-kidney transplant patient is presented. A 51-year-old man underwent a deceased kidney transplantation for focal segmental glomerulosclerosis. Shortly after the kidney transplantation, he received multiple plasmapheresis with additional steroid treatments for cellular rejection and reoccurrence of his primary kidney disease. Three weeks after the kidney transplant, he developed a disseminated adenovirus infection with subsequent acute liver failure. Despite the early diagnosis and aggressive treatment, the patient died. Patients with organ transplantation with autoimmune background etiology are usually over-immunosuppressed to avoid early rejection. In this population, opportunistic infections are not rare. Fever, general malaise, and transplant organ dysfunction are the first signs of bacterial or viral infection. Early infectious diseases work-up, including tissue biopsy, is fundamental to establish a diagnosis. Broad antibiotic and possible antiviral aggressive treatment are mandatory.


  • Clinical Aspect of Cytokines and Chemokines in Liver Transplant

    by Plamen Mihaylov, Burcin Ekser, Jonathan Fridell, Shekhar Kubal


  • Donor‐recipient body size mismatch has no impact on outcomes after deceased donor whole liver transplantation: Role of donor liver size measurement

    by Chandrashekhar A. Kubal, Plamen Mihaylov, Jonathan Fridell, Arianna Cabrales, Tejas Nikumbh, Lava Timsina, Daiki Soma, Burcin Ekser, Richard Mangus

    The role of donor‐recipient body size mismatch (DRSM) on outcomes after whole liver transplantation (LT) is not clearly defined. At our center, in presence of considerable DRSM, objective assessment of the donor liver by a radiology or intraoperative evaluation by procuring surgeon was incorporated. To evaluate the impact of DRSM on graft outcomes with this approach, adult deceased donor whole liver transplants between July 2001 and December 2017 at our center were studied. DRSM was considered when the donor‐recipient body surface area (BSA) ratio (DR‐BSAr) was either 1.25. There were 54 (3.2%) transplants with DR‐BSAr 1.25. One‐year graft survival was 85% vs. 89% vs. 89%; (p = .64) for transplants with DR‐BSArs of 1.25, respectively. Early allograft dysfunction (EAD) (28% vs. 27% vs. 37%; p = .07), post‐transplant coagulopathy, bilirubinemia, and renal function were also comparable. In conclusion, with the actual measurement of the donor liver and recipient abdominal cavity, significant DRSM did not have a negative impact on early and long‐term outcomes. Routine measurement of donor liver size by radiology may be incorporated in liver allocation to improve utilization.


  • Open Access

    Reconstruction of Aberrant Left Hepatic Artery in Orthotopic Liver Transplantation – Single Center Experience

    by Plamen Mihaylov, Burcin Ekser, Daiki Soma, Andrew Lutz, Jonathan Fridell, Chandrashekhar A. Kubal

    One of the most feared complications in liver transplantation is hepatic arterial thrombosis (HAT). The incidence of HAT in liver transplantation varies from 1.2% and 8%. One of the risk factors for this complication is anatomical complexity of hepatic arterial system. The focus of this short communication is to show our approach in dealing with aberrant left hepatic artery in settings of liver transplantation. This is a single center experience. Between January 2016 and June 2019, we procured and transplanted 357 adult liver allografts. Of these, there were 34 (9.5%) livers with aberrant left hepatic artery. All of them have been reconstructed on bench table. There was no incidence of HAT in the entire cohort with ALHA. The one-year graft survival for this patient cohort was 93.1%. Our surgical approach resulted in a low incidence of HAT of 1% with excellent graft survival.

  • Open Access

    Prognostic Impact of Peritransplant Serum Sodium Concentrations in Liver Transplantation

    by Plamen Mihaylov, Shunji Nagai, Burcin Ekser, Richard Mangus, Jonathan Fridell, Chandrashekhar Kubal

    BACKGROUND Serum sodium (Na) is considered to reflect the severity of liver cirrhosis. In the last few years, much effort has been made to integrate this association into prognostic models after liver transplantation. The aim of this study was to investigate the associations between peritransplant Na and neurological complications, as well as short-term survival, after liver transplantation. MATERIAL AND METHODS A total of 306 liver transplantations between 2012 and 2015 were evaluated. Pre- and posttransplant sodium concentrations were investigated with regard to 3-month survival and incidence of posttransplant neurological complications, along with other factors present in the operative side of the recipient and donor. RESULTS The 3-month survival rate was 94%. Neither hyponatremia (145 mEq/L) at pretransplantion predicted 3-month survival. A large amount of intraoperative blood transfusion and a large delta Na showed a significant association with poor outcomes at 3 months. On multivariate analysis, the requirement of blood transfusion and warm ischemia time remained independent prognostic factors for 3-month mortality. Hyponatremia and a large delta Na tended to lead to the frequent development of neurological complications. These complications, secondary to rapid Na correction, were concerning and potentially led to a prolonged hospital stay and early mortality. CONCLUSIONS Rapid change in the sodium level might be caused by large amounts of blood transfusion products. This leads to a diminished short-term survival, as well as a higher rate of neurological complications.